{"name":"CG Oncology","slug":"cg-oncology","ticker":"CGON","exchange":"NASDAQ","domain":"cgoncology.com","description":"CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretosti","hq":"Irvine, CA","founded":2019,"employees":"142","ceo":"Arjun Balar","sector":"Oncology / Oncolytic Virus Immunotherapy","stockPrice":69.63,"stockChange":-4.37,"stockChangePercent":-5.91,"marketCap":"$6.1B","metrics":{"revenue":5071000,"revenueGrowth":1982.7,"grossMargin":0,"rdSpend":116641000,"netIncome":-160995000,"cash":1076242048,"dividendYield":0,"peRatio":-25.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"CGON-101 patent cliff ($1.2B at risk)","drug":"CGON-101","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"CGON-102 patent cliff ($800M at risk)","drug":"CGON-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"CG Oncology Announces FDA Fast Track Designation for CGON-101","summary":"CG Oncology announced that the FDA has granted Fast Track designation to CGON-101 for the treatment of unresectable or metastatic melanoma.","drugName":"CGON-101","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"CG Oncology Reports Third Quarter 2023 Financial Results","summary":"CG Oncology reported its third quarter 2023 financial results, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"CG Oncology Enters into Collaboration Agreement with Leading Cancer Research Institute","summary":"CG Oncology announced a collaboration agreement with a leading cancer research institute to develop new oncolytic virus immunotherapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering - simplywall.st","headline":"A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-15","type":"pipeline","source":"simplywall.st","summary":"How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts - simplywall.st","headline":"How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-13","type":"pipeline","source":"simplywall.st","summary":"Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge? - simplywall.st","headline":"Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNWZiZ3g4TWpWZ1dPTXVybjMzWlV0WTFWbGRWQWpJOHF0Q1V3SktZTFdUSWhuYUdOUU9faXRycXF6WTNXSlJhdFZTUjQyWVBidnpoTDBRRFBMUm5Mc295Z2tDUDZpSGhDRDM0UC12MllYLXN2ZkIyQUVwU0RTLXNxU3F5V0tfWFp2RTdhNFRkYWpaekg1aE1vUFFDWU14dEVLU29YNDJkbVI3VkxhTlpCVUZlNDk0c2RRQzBQSUY3bk9vcmhPY3h5ZEZtWkh1Q0ZXZFJYQzhGTUl6WnJIaHfSAeMBQVVfeXFMTVRxWGxnRk0yOXBEV2xOdnhpck1KT3hURzk4TFdZRlRjblZkOUpKRVJIOVd0MHpiNWxVMWlqRXl0eVpwUEc5NE40c2ZIM2RnRVlzOElKbk9oU29GT3FjdWxyQlFlcWo2dmRMWTl0WUc1LWVpZFdFbGFvUjhETks5YWFhclNCWlM1c1Y3a0Z0VlJWamxHQWJYMnhNdzMtOVM3S09HUGVSS2Q1Z1NWODdHU29GVlZtWWpxalJfSjNleF9sclB4TzhyN3RDa29FVUZGS0s4aDJrNk9WVXFqWDI0T1p5elU?oc=5","date":"2026-03-11","type":"pipeline","source":"simplywall.st","summary":"CG Oncology (CGON) Valuation Check After Strong Recent Share Price Momentum - simplywall.st","headline":"CG Oncology (CGON) Valuation Check After Strong Recent Share Price Momentum","sentiment":"neutral"},{"date":"2026-02-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOY0Y0R0VwczF3NE5FTGZhNDhEWFREVHJvMm1VY0tmbmhXRFdEUlpCWDE1RU83eXVwY3BpSE9acGRRQVIxR2x0R1BobUxfZktiUzhQMk1GSlFrcHdwZ2FYLVdTbXY2dmtTdTBCM3l5Y1RrTG9XR000a21Lc2MxTVRrN1Z0Y01IVGpRajJBVEdKYmFnS2Vfc2RfeWhkZktfdUR5Rzd5NU85TU5oMWkzQ3VWcWcyY3VaeGg5N29pVTA4dzlTZjlaNlVBRk8tQXdWRlBwREFXVjFZcGZhLWRFS0lkV2ZUYlFPV0VBWkFmc0d0UmhUcmdoZUVqNkl6YXVnLXZTNE8yVHppWi00Yk9X?oc=5","date":"2026-01-22","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON)","sentiment":"neutral"},{"date":"2026-01-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQVHBoY2s3QXhsWjNsdEUzNlNwMk1IM0lfbmJFUTVUel9oOE9KeERKcEc1aWdnbVNQU05vY1N0NXNyMFE4UHVBY0FYYTl2TWNlZHdObVI2UU5EV1VFMVJTQVVoNFNrM282TW5BRUR0dWJ0WW1yTFNGRDA0SDl4NG1UUHFB?oc=5","date":"2026-01-09","type":"pipeline","source":"Yahoo Finance","summary":"Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance","headline":"Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge?","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ3Mta3RIUHFwY3FKMzM1b001ZkF2T3hSY24wckR2bVozcEZ0djA5X25jS1A2cmFnV3ZRWHNLd2FUQVBPa0dMVTdOR2FOTHVIcXdfYmpfR1BrejdPbTJoSUg1TF9MdmhsMENuYTY1a1VsZXpsVnZ1ZU1jb1llbkx6RG9FLVhHbFV1MFFDd19R?oc=5","date":"2025-12-23","type":"pipeline","source":"Seeking Alpha","summary":"CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha","headline":"CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOa3FyVXNvaFdDbUpYNV9uWUhPeDNWSnA4S2tqVFlMZTBoeXkteWJlUzBELV9oRENYZzhxSW5zVUxtUUJkV2tlOTV0dVoycFlzWkd1ZGJ0RnFYam1vNzRSV0xwYmNyc0lMemIxYUdmdEd2LUhfQXlMSzd0Q1VlR1ExdExDRUtrdUd0bjRHc1FneThkcV9LcFE?oc=5","date":"2025-11-26","type":"pipeline","source":"Quiver Quantitative","summary":"CG Oncology Appoints Christina Rossi to Board of Directors - Quiver Quantitative","headline":"CG Oncology Appoints Christina Rossi to Board of Directors","sentiment":"neutral"},{"date":"2025-11-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[{"drugName":"CGON-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"CGON-102","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":800000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Biontech","Moderna Therapeutics","Amgen"],"therapeuticFocus":["Oncology","Immunotherapy"],"financials":{"source":"sec_edgar+yahoo","revenue":4040000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":4040000},{"period":"2024-12-31","value":1139000},{"period":"2023-12-31","value":204000},{"period":"2022-12-31","value":191000}],"grossProfit":-607000,"grossProfitHistory":[{"period":"2025-12-31","value":-607000},{"period":"2024-12-31","value":1139000},{"period":"2023-12-31","value":204000}],"rdSpend":116641000,"rdSpendHistory":[{"period":"2025-12-31","value":116641000},{"period":"2024-12-31","value":82102000},{"period":"2023-12-31","value":45752000},{"period":"2022-12-31","value":29029000}],"sgaSpend":73526000,"operatingIncome":-190774000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-190774000},{"period":"2024-12-31","value":-114666000},{"period":"2023-12-31","value":-55449000},{"period":"2022-12-31","value":-35246000}],"netIncome":-160995000,"netIncomeHistory":[{"period":"2025-12-31","value":-160995000},{"period":"2024-12-31","value":-88039000},{"period":"2023-12-31","value":-48607000},{"period":"2022-12-31","value":-35443000}],"eps":-1.41,"epsHistory":[{"period":"2024-12-31","value":-1.41},{"period":"2023-12-31","value":-15.65},{"period":"2022-12-31","value":-11.71},{"period":"2021-12-31","value":-0.54549}],"cash":32490000,"cashHistory":[{"period":"2025-12-31","value":32490000},{"period":"2024-12-31","value":257068000},{"period":"2023-12-31","value":8266000},{"period":"2022-12-31","value":88143000}],"totalAssets":791592000,"totalLiabilities":38990000,"totalDebt":7021000,"equity":752602000,"operatingCashflow":-132346000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-132346000},{"period":"2024-12-31","value":-78713000},{"period":"2023-12-31","value":-45679000},{"period":"2022-12-31","value":-29804000}],"capex":-134000,"capexHistory":[{"period":"2025-12-31","value":-134000},{"period":"2024-12-31","value":-234000},{"period":"2022-12-31","value":-14000},{"period":"2021-12-31","value":-97000}],"freeCashflow":-132480000,"dividendsPaid":null,"buybacks":null,"employees":142,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":17994000,"ebit":-48700000,"ebitda":-47851000,"period":"2025-12-31","revenue":2322000,"epsBasic":null,"netIncome":-41309000,"rdExpense":29958000,"epsDiluted":null,"grossProfit":-748000,"operatingIncome":-48700000},{"sga":23334000,"ebit":-51129000,"ebitda":-50713000,"period":"2025-09-30","revenue":1666000,"epsBasic":-0.57,"netIncome":-43808000,"rdExpense":27884000,"epsDiluted":-0.57,"grossProfit":89000,"operatingIncome":-51129000},{"sga":17410000,"ebit":-48741000,"ebitda":-48585000,"period":"2025-06-30","revenue":0,"epsBasic":-0.54,"netIncome":-41426000,"rdExpense":31331000,"epsDiluted":-0.54,"grossProfit":null,"operatingIncome":-48741000},{"sga":14789000,"ebit":-42204000,"ebitda":-42180000,"period":"2025-03-31","revenue":52000,"epsBasic":-0.45,"netIncome":-34452000,"rdExpense":27467000,"epsDiluted":-0.45,"grossProfit":null,"operatingIncome":-42204000},{"sga":11705000,"ebit":-38049000,"ebitda":-38049000,"period":"2024-12-31","revenue":456000,"epsBasic":null,"netIncome":-31798000,"rdExpense":26800000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-38049000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.3,"netIncome":null,"rdExpense":null,"epsDiluted":-0.3,"grossProfit":43000,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":69.63,"previousClose":74,"fiftyTwoWeekHigh":75.5,"fiftyTwoWeekLow":23.38,"fiftyTwoWeekRange":"23.376 - 75.5","fiftyDayAverage":66.89,"twoHundredDayAverage":47.6,"beta":0.42,"enterpriseValue":5458315776,"forwardPE":-25.7,"priceToBook":5.61,"priceToSales":1211.11,"enterpriseToRevenue":1076.38,"enterpriseToEbitda":-25.66,"pegRatio":0,"ebitda":-212696992,"ebitdaMargin":0,"freeCashflow":-105890376,"operatingCashflow":-160012000,"totalDebt":7575000,"debtToEquity":0.7,"currentRatio":31.3,"returnOnAssets":-14.4,"returnOnEquity":-20.8,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":89.64,"targetHighPrice":108,"targetLowPrice":77,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.2,"institutionHeldPercent":100.2,"sharesOutstanding":88202473,"floatShares":72774978,"sharesShort":9222491,"shortRatio":8.23,"shortPercentOfFloat":10.5,"epsTrailing":-2.34,"epsForward":-2.71,"revenuePerShare":0.06,"bookValue":12.4,"officers":[{"age":34,"name":"Mr. Arthur  Kuan","title":"Chairman & CEO"},{"age":54,"name":"Mr. Ambaw  Bellete M.S.","title":"President & COO"},{"age":60,"name":"Mr. James M. DeTore","title":"Chief Financial Officer"},{"age":48,"name":"Mr. Joshua F. Patterson","title":"General Counsel, Chief Compliance Officer & Secretary"},{"age":57,"name":"Dr. Vijay  Kasturi M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. Swapnil  Bhargava Ph.D.","title":"Chief Technical Officer"},{"age":null,"name":"Ms. Amy  Steele","title":"Vice President of Finance & Administration"},{"age":null,"name":"Ms. Sarah  Connors","title":"Vice President of Communications & Patient Advocacy"}],"industry":"Biotechnology","irWebsite":"","website":"https://cgoncology.com","phone":"949 409 3700"}}